Swiss drug major Novartis (NOVN: VX) said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology, will leave the company with immediate effect having decided to “pursue a career opportunity outside of the organization.”
Alessandro Riva, global head of Novartis oncology development and medical affairs, will take on the role of president of Novartis Oncology on an interim basis, in addition to his current role, until a successor is named in due course, said Novartis.
To become president and CEO of Incyte
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze